American Marconi Wireless News - Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

NYSE - LSE

RBGPF	0.12%	82.5	$
CMSC	0.28%	22.895	$
BCC	-3.01%	69.74	$
VOD	-0.31%	14.325	$
NGG	-1.91%	85.76	$
GSK	-0.01%	52.055	$
RYCEF	-4.73%	15.85	$
RELX	0.38%	33.99	$
RIO	-4.18%	84.2	$
BCE	0.43%	25.86	$
JRI	-0.84%	12.22	$
CMSD	0.17%	22.93	$
BTI	-0.19%	57.98	$
AZN	-0.21%	188.03	$
BP	4.24%	46.585	$

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

BOULEVARD 13.01.2026

DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.

Text size:

The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/aytu. A replay will also be available through the same links.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

A.Malone--AMWN

Featured

Wimbledon expansion plan gets legal boost

Social media addiction trial jury deliberations continue

Black Book Research Releases 2026 Market Report on Spanish-Speaking Latin America, Finding 18 Distinct Digital Healthcare Buyer Environments Reshaping EHR, Interoperability, Analytics, and RCM Investment

Remergify Announces Strategic Partnership with Farrington Capital Group and Near Infrared Imaging, Inc to Incorporate AI into Near-Infrared Medical Technology